Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated

Sabanci P. A., ERGÜVEN M., YAZIHAN N., Aktas E., Aras Y., Civelek E., ...Daha Fazla

NEUROLOGICAL RESEARCH, cilt.36, sa.3, ss.189-197, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 3
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1179/1743132813y.0000000283
  • Dergi Adı: NEUROLOGICAL RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.189-197
  • Anahtar Kelimeler: Combination chemotherapy, Glioblastoma, Lithium chloride, Midkine, Sorafenib, GLYCOGEN-SYNTHASE KINASE-3, HEPATOCELLULAR-CARCINOMA, IMATINIB MESYLATE, BREAST-CANCER, GLIOMA-CELLS, INHIBITION, RESISTANCE, APOPTOSIS, PATHWAYS, LINES
  • Ankara Üniversitesi Adresli: Evet

Özet

Objectives: The objectives of this study were to test the effects of the new combination treatment modality, sorafenib (SOR) and lithium chloride (LiCl) and to assess whether midkine (MK) protein has a role in any potential effects.